PDS Biotechnology PDSB 深 沪
已收盘 11-13 16:00:00 美东时间
0.8726
-0.107
-10.96%
华盛通- 最 高0.99
- 今 开0.99
- 成交量 596.16万股
- 最 低 0.75
- 昨 收 0.98
- 总市值 6324.10万
- 52周最高 1.79
- 市盈率 静 --
- 换手率 8.23%
- 52周最低 0.1952
- 委 比 -93.10%
- 总股本 7247.42万
- 历史最高 17.85
- 量 比 1.74
- 振 幅 24.49%
- 历史最低 0.1952
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PDS Biotechnology Q3 EPS $(0.11) Misses $(0.09) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 42.11 percent increase over losses of $(0.19) per share from the same period last year.
11-13 21:14
PDS Biotech Reports Third Quarter 2026 Financial Results
PDS Biotech reported Q3 2026 updates, completing a $22.3M PIPE financing led by Nant Capital and appointing new board members. The company highlighted clinical progress for its lead program PDS0301 and secured new patents. Financially, cash reserves stood at $15.2M, with a net loss of $7.6M, down from $9.0M in Q3 2025. R&D expenses decreased by $2.5M, while G&A costs rose slightly.
11-13 13:00
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
PRINCETON, N.J., Nov. 10, 2026 – PDS Biotechnology Corporation announced that NantWorks exercised its warrants to purchase 17,699,115 shares of the Company's common stock at $0.22 per share, generating approximately $3.9 million in gross proceeds. The funds will support advancing PDS0301 toward a Phase 3 trial for metastatic colorectal cancer, as well as the Company’s partnership strategy for PDS0101 and general corporate purposes. The warrants w...
11-10 13:00
美股大行评级 | 潜在涨幅1112.12%！Canaccord Genuity上调Wave Life Sciences目标价至44美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences"买入"评级，目标价从42美元升至44美元；Canaccord Genuity：维持Pharming Group"买入"评级，目标价从38美元升至41美元
10-30 12:30
B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4
B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
10-30 01:11
PDS Biotechnology highlights oncology pipeline and PDS0301 progress
PDS Biotechnology ( ($PDSB) ) has issued an announcement. On October 20, 2026, ...
10-21 18:29
PDS Biotechnology Reshapes Board with New Director Appointments
The latest update is out from PDS Biotechnology ( ($PDSB) ). On October 18, 202...
10-20 20:28
PDS Biotechnology Highlights PDS0301 Data in KOL Event
An announcement from PDS Biotechnology ( ($PDSB) ) is now available. On October...
10-06 20:29
PDS Biotech highlights strong Phase 2 PDS0101 results
PDS Biotechnology ( ($PDSB) ) has shared an announcement. On September 22, 2026...
09-22 20:51
PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology C...
09-22 20:08
